Dr. Yasuhiro Koh is an oncologist from Shizuoka Cancer Center presented on kinase activity profiling to identify biomarkers predictive of tumor response in lung & gastric cancer. He has a background as a thoracic oncologist and he is now focusing on the research bridging the gap between bench and bedside his lab.
He is working closely with the clinical team at his cancer center in Japan and he is conducting many research projects using clinical samples. Dr. Yasuhiro Koh's goal is to implement personalized medicine by elucidating cancer biology.
Somatic mutations such as EGFR and KRAS have been identified as therapeutic targets and genetic testing of patients with advanced non-small cell lung cancer and colorectal cancer has become routine clinical practice. Moreover, comprehensive multiplexed mutational testing is now necessary to assign the patients to the appropriate therapy. To improve anticancer therapy, further therapeutic targets and predictive biomarkers need to be identified.
In this webinar, I will talk about the incorporation of mutational testing into the clinic at Shizuoka Cancer Center and our approach for exploring new targets and predictive biomarkers using PamGene technology in lung cancer and gastric cancer.